Scott M Schuetze1, Vanessa Bolejack2, Edwin Choy3, Kristen N Ganjoo4, Arthur P Staddon5, Warren A Chow6, Hussein A Tawbi7, Brian L Samuels8, Shreyaskumar R Patel7, Margaret von Mehren9, Gina D'Amato10, Kirsten M Leu11, David M Loeb12, Charles A Forscher13, Mohammed M Milhem14, Daniel A Rushing15, David R Lucas1, Rashmi Chugh1, Denise K Reinke16, Laurence H Baker1. 1. University of Michigan, Ann Arbor, Michigan. 2. Cancer Research and Biostatistics, Seattle, Washington. 3. Massachussetts General Hospital, Boston, Massachusetts. 4. Stanford University, Palo Alto, California. 5. University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 6. City of Hope Medical Center, Duarte, California. 7. The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Northwest Oncology, Post Falls, Idaho. 9. Fox Chase Cancer Center, Philadelphia, Pennsylvania. 10. Georgia Cancer Specialists, Sandy Springs, Georgia. 11. Nebraska Cancer Specialists, Omaha, Nebraska. 12. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 13. Cedars-Sinai Medical Center, Los Angeles, California. 14. University of Iowa, Iowa City, Iowa. 15. Indiana University, Indianapolis, Indiana. 16. Sarcoma Alliance Through Research and Collaboration, Ann Arbor, Michigan.
Abstract
BACKGROUND: Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that are relatively resistant to chemotherapy and for which more effective drug therapy is needed. METHODS: The 5 listed subtypes were enrolled into a single indolent sarcoma cohort in a phase 2 study of dasatinib using a Bayesian continuous monitoring rule for enrollment. The primary objective was to estimate the 6-month progression-free survival (PFS) rate according to the Choi criteria with a target of ≥50%. Cross-sectional imaging was performed before the start of treatment, every 2 months for 6 months, and then every 3 months during treatment. The 2- and 5-year survival rates were determined. RESULTS: One hundred sixteen patients were enrolled within 45 months, and 109 began treatment with dasatinib. The 6-month PFS rate and the median PFS were 48% and 5.8 months, respectively. The PFS rate at 6 months was highest with ASPS (62%) and lowest with SFT (30%). More than 10% of the patients with ASPS, CS, or chordoma had stable disease for more than 1 year. Collectively, for all 5 subtypes, the 2- and 5-year overall survival rates were 44% and 13%, respectively. An objective response was observed in 18% of the patients with CS or chordoma. CONCLUSIONS: Dasatinib failed to achieve control of sarcoma growth for at least 6 months in more than 50% of the patients in this trial according to the Choi tumor response criteria. An objective tumor response and prolonged stable disease was observed in >10% of patients with CS or chordoma. Cancer 2017;90-97.
BACKGROUND:Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that are relatively resistant to chemotherapy and for which more effective drug therapy is needed. METHODS: The 5 listed subtypes were enrolled into a single indolent sarcoma cohort in a phase 2 study of dasatinib using a Bayesian continuous monitoring rule for enrollment. The primary objective was to estimate the 6-month progression-free survival (PFS) rate according to the Choi criteria with a target of ≥50%. Cross-sectional imaging was performed before the start of treatment, every 2 months for 6 months, and then every 3 months during treatment. The 2- and 5-year survival rates were determined. RESULTS: One hundred sixteen patients were enrolled within 45 months, and 109 began treatment with dasatinib. The 6-month PFS rate and the median PFS were 48% and 5.8 months, respectively. The PFS rate at 6 months was highest with ASPS (62%) and lowest with SFT (30%). More than 10% of the patients with ASPS, CS, or chordoma had stable disease for more than 1 year. Collectively, for all 5 subtypes, the 2- and 5-year overall survival rates were 44% and 13%, respectively. An objective response was observed in 18% of the patients with CS or chordoma. CONCLUSIONS:Dasatinib failed to achieve control of sarcoma growth for at least 6 months in more than 50% of the patients in this trial according to the Choi tumor response criteria. An objective tumor response and prolonged stable disease was observed in >10% of patients with CS or chordoma. Cancer 2017;90-97.
Authors: Annemiek van Maldegem; Anthony P Conley; Piotr Rutkowski; Shreyaskumar R Patel; Iwona Lugowska; Ingrid M E Desar; Judith V M G Bovée; Hans Gelderblom Journal: Oncologist Date: 2018-08-06
Authors: Scott M Schuetze; Vanessa Bolejack; Dafydd G Thomas; Margaret von Mehren; Shreyaskumar Patel; Brian Samuels; Edwin Choy; Gina D'Amato; Arthur P Staddon; Kristen N Ganjoo; Warren A Chow; Daniel A Rushing; Charles A Forscher; Dennis A Priebat; David M Loeb; Rashmi Chugh; Scott Okuno; Denise K Reinke; Laurence H Baker Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639
Authors: J G van Oosterwijk; M A J H van Ruler; I H Briaire-de Bruijn; B Herpers; H Gelderblom; B van de Water; J V M G Bovée Journal: Br J Cancer Date: 2013-08-06 Impact factor: 7.640